Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elevance Health, Inc. stock logo
ELV
Elevance Health
$446.57
+4.0%
$407.13
$362.21
$567.26
$101.10B0.771.40 million shs1.68 million shs
Medtronic plc stock logo
MDT
Medtronic
$88.43
-0.5%
$91.04
$75.96
$96.25
$113.42B0.86.57 million shs4.01 million shs
Sanofi stock logo
SNY
Sanofi
$54.82
+1.6%
$55.33
$45.22
$60.12
$139.12B0.582.27 million shs1.00 million shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$488.16
+1.0%
$479.96
$377.85
$519.88
$125.35B0.411.28 million shs938,364 shs
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elevance Health, Inc. stock logo
ELV
Elevance Health
-0.84%-0.22%+8.53%+17.37%-13.99%
Medtronic plc stock logo
MDT
Medtronic
+0.55%+0.91%-5.55%+10.91%+4.42%
Sanofi stock logo
SNY
Sanofi
-0.72%-1.01%-4.55%+11.95%+13.10%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-0.26%-3.36%+0.04%+19.16%+18.09%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elevance Health, Inc. stock logo
ELV
Elevance Health
4.643 of 5 stars
3.53.04.20.04.22.52.5
Medtronic plc stock logo
MDT
Medtronic
4.3274 of 5 stars
2.24.03.34.02.92.50.6
Sanofi stock logo
SNY
Sanofi
3.3635 of 5 stars
2.53.02.50.04.00.02.5
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
3.8022 of 5 stars
2.33.00.03.32.92.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elevance Health, Inc. stock logo
ELV
Elevance Health
2.94
Moderate Buy$519.8116.40% Upside
Medtronic plc stock logo
MDT
Medtronic
2.44
Hold$96.078.64% Upside
Sanofi stock logo
SNY
Sanofi
3.00
Buy$62.5014.01% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.65
Moderate Buy$509.174.30% Upside

Current Analyst Ratings Breakdown

Latest MDT, ELV, SNY, and VRTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$408.00 ➝ $420.00
3/31/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$555.00 ➝ $567.00
3/28/2025
Elevance Health, Inc. stock logo
ELV
Elevance Health
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
3/21/2025
Sanofi stock logo
SNY
Sanofi
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$65.00
3/17/2025
Elevance Health, Inc. stock logo
ELV
Elevance Health
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$450.00
3/4/2025
Medtronic plc stock logo
MDT
Medtronic
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$92.00 ➝ $107.00
2/20/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$407.00 ➝ $408.00
2/19/2025
Medtronic plc stock logo
MDT
Medtronic
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$105.00 ➝ $105.00
2/19/2025
Medtronic plc stock logo
MDT
Medtronic
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$85.00 ➝ $95.00
2/19/2025
Medtronic plc stock logo
MDT
Medtronic
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
2/19/2025
Medtronic plc stock logo
MDT
Medtronic
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$90.00 ➝ $91.00
(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elevance Health, Inc. stock logo
ELV
Elevance Health
$176.81B0.57$44.79 per share9.97$178.62 per share2.50
Medtronic plc stock logo
MDT
Medtronic
$33.20B3.42$7.24 per share12.21$38.69 per share2.29
Sanofi stock logo
SNY
Sanofi
$44.29B3.14$5.40 per share10.16$33.20 per share1.65
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$11.02B11.38N/AN/A$63.90 per share7.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elevance Health, Inc. stock logo
ELV
Elevance Health
$5.98B$25.6117.4411.441.183.38%18.28%6.72%4/22/2025 (Estimated)
Medtronic plc stock logo
MDT
Medtronic
$3.68B$3.2926.8815.172.2212.83%14.07%7.70%5/21/2025 (Estimated)
Sanofi stock logo
SNY
Sanofi
$6.02B$2.4922.0211.541.0112.77%25.61%14.72%4/24/2025 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-$535.60M-$2.20N/A27.882.11-4.86%-2.02%-1.49%5/5/2025 (Estimated)

Latest MDT, ELV, SNY, and VRTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2025N/A
Sanofi stock logo
SNY
Sanofi
$0.87N/AN/AN/A$9.79 billionN/A
4/22/2025N/A
Elevance Health, Inc. stock logo
ELV
Elevance Health
$10.60N/AN/AN/A$46.26 billionN/A
2/18/2025Q3 2025
Medtronic plc stock logo
MDT
Medtronic
$1.36$1.39+$0.03$1.01$8.33 billion$8.29 billion
2/10/2025Q4 2024
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.99$3.54-$0.45$3.50$2.78 billionN/A
1/30/2025Q4 2024
Sanofi stock logo
SNY
Sanofi
$0.70$0.70N/A$0.29$10.57 billionN/A
1/23/2025Q4 2024
Elevance Health, Inc. stock logo
ELV
Elevance Health
$3.80$3.84+$0.04$1.81$44.63 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elevance Health, Inc. stock logo
ELV
Elevance Health
$6.841.53%+12.99%26.71%14 Years
Medtronic plc stock logo
MDT
Medtronic
$2.803.17%+4.14%85.11%48 Years
Sanofi stock logo
SNY
Sanofi
$1.472.68%+1.84%59.04%N/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest MDT, ELV, SNY, and VRTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/6/2025
Medtronic plc stock logo
MDT
Medtronic
quarterly$0.703%3/28/20253/28/20254/11/2025
1/22/2025
Elevance Health, Inc. stock logo
ELV
Elevance Health
quarterly$1.711.75%3/10/20253/10/20253/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elevance Health, Inc. stock logo
ELV
Elevance Health
0.71
1.45
1.50
Medtronic plc stock logo
MDT
Medtronic
0.48
1.90
1.39
Sanofi stock logo
SNY
Sanofi
0.15
1.46
1.14
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.01
2.69
2.35

Institutional Ownership

CompanyInstitutional Ownership
Elevance Health, Inc. stock logo
ELV
Elevance Health
89.24%
Medtronic plc stock logo
MDT
Medtronic
82.06%
Sanofi stock logo
SNY
Sanofi
14.04%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Insider Ownership

CompanyInsider Ownership
Elevance Health, Inc. stock logo
ELV
Elevance Health
0.35%
Medtronic plc stock logo
MDT
Medtronic
0.20%
Sanofi stock logo
SNY
Sanofi
1.00%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elevance Health, Inc. stock logo
ELV
Elevance Health
102,300226.39 million231.11 millionOptionable
Medtronic plc stock logo
MDT
Medtronic
95,0001.28 billion1.28 billionOptionable
Sanofi stock logo
SNY
Sanofi
91,6002.54 billion2.51 billionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,100256.79 million256.28 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Elevance Health stock logo

Elevance Health NYSE:ELV

$446.57 +17.24 (+4.02%)
As of 01:46 PM Eastern

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Medtronic stock logo

Medtronic NYSE:MDT

$88.43 -0.43 (-0.48%)
As of 01:47 PM Eastern

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Sanofi stock logo

Sanofi NASDAQ:SNY

$54.82 +0.87 (+1.61%)
As of 01:46 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$488.16 +4.67 (+0.97%)
As of 01:46 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.